If You Invested in First Tracks Biotherapeutics, Inc. (TRAXV)
See the TRAXV overviewTRAXV has not traded since Apr 17, 2026. Its last close was $22.51, so every figure on this page ends there and the 1, 5 and 10 year results count back from that close.
$1,000 invested 1 Year Before Its Last Close
N/A
Our prices start Apr 6, 2026
$1,000 invested 5 Years Before Its Last Close
N/A
Our prices start Apr 6, 2026
$1,000 invested 10 Years Before Its Last Close
N/A
Our prices start Apr 6, 2026
What $1,000 or $10,000 in TRAXV Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Apr 6, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $1,185 +18% |
| $10,000 | — | — | — | $11,847 +18% |
Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for TRAXV$1,000 Investment Over Time
TRAXV vs S&P 500Year-by-Year Returns
TRAXV annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026Apr 6, 2026 to Apr 17, 2026 | $19.00 | $22.51 | +18.5% | +18.5% |
About First Tracks Biotherapeutics, Inc.
Healthcare · NASDAQ
Last Close
$22.51
Similar Stocks
See how related companies performed
Frequently Asked Questions
First Tracks Biotherapeutics, Inc. investment returns
How much was $1,000 invested in First Tracks Biotherapeutics, Inc. worth at its last close?
Limited historical data is available for TRAXV. Our price data for TRAXV starts on Apr 6, 2026.
Has First Tracks Biotherapeutics, Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare TRAXV performance over available time periods.
For informational and educational purposes only, not investment advice.
